XOMA Corporation




Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-04-22 pm EDT 5-day change 1st Jan Change
25.82 USD +1.33% Intraday chart for XOMA Corporation +6.08% +39.57%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
XOMA Corporation completed the acquisition of Kinnate Biopharma Inc.. CI
XOMA Corporation Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Sector Update: Health Care Stocks Advance Friday Afternoon MT
XOMA Agrees to Acquire Kinnate Biopharma MT
XOMA Corporation entered into a definitive merger agreement to acquire Kinnate Biopharma Inc. for approximately $120 million. CI
XOMA Acquires Interest in Pain Management Medication Dsuvia for $8 Million MT
XOMA Corporation acquired DSUVIA® of Talphera, Inc. for $8 million. CI
XOMA Names Owen Hughes CEO, Jack Wyszomierski Chairman; to Make $1 Million Milestone Payment MT
Xoma to Make $1 Million Milestone Payment to LadRx After FDA Accepts Zevra Application for Arimoclomol DJ
Xoma Names Owen Hughes as Chief Executive Officer CI
Xoma Appoints Jack L. Wyszomierski as Chairman of the Board of Directors CI
XOMA Authorizes $50 Million Share Buyback Program MT
XOMA Authorizes $50 Million Share Buyback Program MT
XOMA Corporation announces an Equity Buyback for $50 million worth of its shares. CI
XOMA Corporation authorizes a Buyback Plan. CI
Sector Update: Health Care Stocks Gain in Afternoon Trading MT
Xoma Gets Up To $140 Million Royalty-Backed Loan From Blue Owl Capital; Xoma Shares Rise MT
Xoma-Non-Dilutive, Non-Recourse, Royalty-Backed Loan For Up To $140 Million Of Capital RE
XOMA Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Earnings Flash (XOMA) XOMA CORPORATION Reports Q3 Revenue $830,000 MT
XOMA Earns $5 Million Milestone Upon US FDA Acceptance of Day One Biopharmaceuticals' NDA for Glioma Therapy MT
ObsEva to Return Global Rights on Ebopiprant to Xoma MT
HC Wainwright Adjusts Price Target on XOMA to $74 From $69, Maintains Buy Rating MT
Earnings Flash (XOMA) XOMA CORPORATION Posts Q2 Revenue $1.7M MT
XOMA Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Chart XOMA Corporation
More charts
XOMA Corporation is a biotechnology royalty aggregator. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to larger pharmaceutical partners. The Company has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. Its royalty portfolio includes DAY101 (tovorafenib), JNJ-63723283 (cetrelimab), RZ358, arimoclomol, TAK-079 (mezagitamab), BAY-1213790 (osocimab), AFM13 (acimtamig), AB023 (gruticibart), AB002 (E-WE thrombin), AB054, AV-299 (ficlatuzumab), COM902, vosaroxin, aldoxorubicin, INCAGN2385, INCAGN02390, MNPR-101, PBF-680, PBF-677, PBF-999, PBF-1129, PBF-1650, G03-52-01, RZ402, DSUVIA (sufentanil sublingual tablet), IXINITY [coagulation factor IX (recombinant)], VABYSMO (faricimab-svoa), CMP-001 (vidutolimod), and CFZ533 (iscalimab).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Mean consensus
Number of Analysts
Last Close Price
25.48 USD
Average target price
74 USD
Spread / Average Target
  1. Stock Market
  2. Equities
  3. XOMA Stock
  4. News XOMA Corporation
  5. Sector Update: Health Care Stocks Advance Friday Afternoon